Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $48.3333.

RAPP has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a research report on Friday, December 19th. BTIG Research restated a “buy” rating and issued a $47.00 price objective on shares of Rapport Therapeutics in a report on Monday, December 8th. HC Wainwright lifted their price objective on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen raised Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday.

Rapport Therapeutics Trading Down 3.5%

NASDAQ:RAPP opened at $26.93 on Monday. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $42.27. The firm has a market cap of $1.28 billion, a PE ratio of -9.94 and a beta of 1.63. The stock has a fifty day moving average price of $28.59 and a 200 day moving average price of $23.85.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. Equities analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Activity

In related news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Monday, December 15th. The shares were sold at an average price of $30.02, for a total transaction of $255,170.00. Following the sale, the insider directly owned 392,642 shares in the company, valued at $11,787,112.84. This trade represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Abraham Ceesay sold 5,833 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $29.64, for a total transaction of $172,890.12. Following the completion of the transaction, the chief executive officer owned 567,913 shares of the company’s stock, valued at $16,832,941.32. This represents a 1.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 67,655 shares of company stock valued at $1,863,705. Insiders own 13.57% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC purchased a new position in shares of Rapport Therapeutics during the second quarter worth approximately $2,270,000. TD Asset Management Inc increased its holdings in shares of Rapport Therapeutics by 20.9% in the 2nd quarter. TD Asset Management Inc now owns 196,870 shares of the company’s stock valued at $2,238,000 after acquiring an additional 34,052 shares during the period. Intech Investment Management LLC purchased a new stake in Rapport Therapeutics in the 2nd quarter valued at $130,000. Tudor Investment Corp ET AL acquired a new stake in Rapport Therapeutics during the 3rd quarter worth $331,000. Finally, Maven Securities LTD purchased a new position in Rapport Therapeutics during the 3rd quarter worth $594,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.